Advertisement

Topics

European Commission approves Pfizer's hard-to-treat leukemia drug Besponsa

05:57 EDT 3 Jul 2017 | Pharmaceutical Business Review

Pfizer has secured approval from the European Commission for BESPONSA (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).

Original Article: European Commission approves Pfizer's hard-to-treat leukemia drug Besponsa

NEXT ARTICLE

More From BioPortfolio on "European Commission approves Pfizer's hard-to-treat leukemia drug Besponsa"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...